Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cranberry Extract
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Recipient : Laval University
Deal Size : Inapplicable
Deal Type : Inapplicable
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
July 05, 2023
Lead Product(s) : Cranberry Extract
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Recipient : Laval University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oat Beta Glucan,Avenanthramides
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Recipient : Ceapro
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, Symrise is guaranteed to purchase minimum annual volumes of Ceapro’s high value active ingredients. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions.
Product Name : Juvente
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 03, 2022
Lead Product(s) : Oat Beta Glucan,Avenanthramides
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Recipient : Ceapro
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Probiotic
Therapeutic Area : Dental and Oral Health
Study Phase : Undisclosed
Recipient : Queen Mary University of London
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of Two Active Lactobacilli for the Maintenance of Gingival Health
Details : Undisclosed
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
September 25, 2017
Lead Product(s) : Probiotic
Therapeutic Area : Dental and Oral Health
Highest Development Status : Undisclosed
Recipient : Queen Mary University of London
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
